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Abstract
Background: Malnutrition and muscle wasting are common in haemodialysis (HD) patients. Their pathogenesis is
complex and involves many molecules including Myostatin (Mstn), which acts as a negative regulator of skeletal
muscle. The characterisation of Mstn as a biomarker of malnutrition could be useful in the prevention and
management of this condition. Previous studies have reported no conclusive results on the actual relationship
between serum Mstn and wasting and malnutrition. So, in this study, we evaluated Mstn profile in a cohort of
regular HD patients.
Methods: We performed a cross-sectional study, enrolling 37 patients undergoing bicarbonate-HD (BHD) or
haemodiafiltration (HDF) at least for six months. 20 sex-matched healthy subjects comprised the control group.
Mstn serum levels were evaluated by ELISA before and after HD. We collected clinical and biochemical data,
evaluated insulin resistance, body composition, malnutrition [by Malnutrition Inflammation Score (MIS)] and tested
muscle function (by hand-grip strength, six-minute walking test and a questionnaire on fatigue).
Results: Mstn levels were not significantly different between HD patients and controls (4.7 ± 2.8 vs 4.5 ± 1.3 ng/ml).
In addition, while a decrease in Mstn was observed after HD treatment, there were no differences between BHD
and HDF. In whole group of HD patients Mstn was positively correlated with muscle mass (r = 0.82, p < 0.001) and
inversely correlated with age (r = − 0.63, p < 0.01) and MIS (r = − 0.39, p = 0.01). No correlations were found between
Mstn and insulin resistance, such as between Mstn levels and parameters of muscle strength and fatigue. In
multivariate analysis, Mstn resulted inversely correlated with fat body content (β = − 1.055, p = 0.002).
Conclusions: Circulating Mstn is related to muscle mass and nutritional status in HD patients, suggesting that it
may have a role in the regulation of skeletal muscle and metabolic processes. However, also considering the lack of
difference of serum Mstn between healthy controls and HD patients and the absence of correlations with muscle
function tests, our findings do not support the use of circulating Mstn as a biomarker of muscle wasting and
malnutrition in HD.
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Background
Patients suffering from chronic kidney disease (CKD),
mainly those undergoing hemodialysis (HD), often present
malnutrition and muscle wasting, which directly correlate
with morbidity and mortality [1]. Aetiology and pathophysi-
ology of these conditions are complex and multifactorial,
involving physical inactivity, insulin resistance, nutritional
and hormonal changes and loss of muscle fibres [2]. Due to
the relevant clinical impact of malnutrition and wasting,
many attempts have been made to find a comprehensive
definition of these conditions, in order to standardize diag-
nostic and therapeutic approaches. The different definitions
took into consideration the levels of putative serum malnu-
trition markers (such as albumin and prealbumin), body
mass index (BMI), the analysis of body composition and
the evaluation of nutritional status by specific question-
naires (such as Subjective Global Assessment, SGA) [3].
However, while it is clear that an adequate evaluation of
nutritional status requires a multistep approach, on the
other hand the individuation of feasible and reproducible
markers, allowing early diagnosis and monitoring of malnu-
trition and muscle wasting, is potentially useful [4].
Recently, the study of molecular and cellular mecha-
nisms involved in the regulation of energy and muscular
homeostasis has gained much interest. Myokines are
molecules produced and released by skeletal muscle cells
with systemic and paracrine actions, related to the acti-
vation of intracellular signalling pathways. These mole-
cules, which include Myostatin, Irisin and IL-6, may
have positive or negative effects on muscle growth and
regulate relevant processes, such as increase fat oxida-
tion, insulin sensitivity and inflammation [5].
The Growth Differentiation Factor (GDF)-8/Myostatin
(Mstn) is a member of the Transforming Growth Factor
(TGF)-β superfamily, primarily expressed in skeletal
muscle cells and found also in other different cells and tis-
sues, such as cardiomyocytes, macrophages and vessels. It
is synthesized as a 376 amino acid pre-propeptide, then
processed into an inhibitory propeptide of 242 amino
acids and an active peptide of 110 amino acids [6].
Mstn exerts its effects in both autocrine and paracrine
ways by binding a cell-bound Activin type II receptor 2B
(ActRIIB) which, assembling itself with ALK4 or ALK5,
leads to the activation of intracellular signalling path-
ways, including Smad 2/3 and Akt [7].
In skeletal muscle, Mstn limits muscle growth and pro-
motes protein breakdown and its inhibitory effects have
been described in both experimental models and clinical
settings, with several studies demonstrating its increased
expression in atrophic muscle and chronic diseases [8].
Although its action on skeletal muscle candidates
serum Mstn as a potential biomarker for muscle wasting,
the relationship between serum Mstn and skeletal
muscle mass is still unclear.
Indeed, while the muscle-wasting effects of tissue
myostatin are well established, many studies investigat-
ing serum Mstn in different disease conditions gave con-
flicting results, showing that Mstn may be both directly
or inversely related to muscle mass or muscle wasting
[9, 10].
In CKD patients an up-regulation of Mstn gene
expression in skeletal muscle has been found, which
was related to IL-6 expression, suggesting a link be-
tween Mstn and microinflammation [11]. Moreover, it
has also been recently described that uremic toxins
may accelerate muscle atrophy, by inducing Mstn ex-
pression [12]. However, only few studies have been
focused on the evaluation of serum Mstn in CKD pa-
tients [13, 14].
Therefore, in this study we tried to characterize the
profile of circulating Mstn and investigate its potentiality




Adult (> 18 years) maintenance HD patients who had
undergone HD for at least 6months were enrolled in a
cross-sectional. We excluded patients with: i) acute dis-
eases, such as infections or immunological disorders, ii)
immunosuppressive therapy, iii) history of transplantation
or cancer. The control group was constituted by sex-
matched healthy subjects.
We enrolled patients undergoing standard low-flux bi-
carbonate hemodialysis (BHD) or on-line hemodiafiltra-
tion (HDF) in a 2:1 ratio. BHD was performed with
cellulose-based membranes using a blood flow rate of
300–350mL/min (DICEA®,©Baxter International, IL,
USA), while HDF was performed with high-flux mem-
branes using a convective volume of 25–30% (FX100 High
−Flux®,©Fresenius Medical Bad Hamburg, Germany).
For each patient we collected: i) clinical data, in-
cluding age, dialysis modality, dialysis vintage and
body mass index (BMI), and ii) biochemical data,
such as pre-dialysis potassium, phosphate, transfer-
rin, albumin, and C-reactive protein (CRP) serum
levels. McAuley index (McA) = exp. [2.63–0.28 ln (in-
sulin in mU/l) – 0.31ln (triglycerides in mmol/l)]
was used to define insulin resistance (IR), consider-
ing a diagnostic cut-off point of ≤5.8 [15]. Serum
Mstn level was tested by ELISA (Quantikine; R&D
Systems, Minneapolis, MN, USA; detection limit 5.3
pg/ml), at the beginning and at the end of the
hemodialysis session.
The study was performed according to the Declaration
of Helsinki and was approved by the local Ethics Com-
mittee (protocol n. 9358/2015). All participants provided
written informed consent before the enrollment.
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Body composition and nutritional evaluations
Body composition was studied by Body Composition
Monitor (BCM, FMC, Bad Homburg, Germany). Mea-
surements were taken before the HD treatment with the
patient supine; electrodes were attached to the hand and
foot on the same side of the body. As previously re-
ported, a 3-compartment model of the body composition
was applied. This model provides data on overhydration
(OH), lean tissue index (LTI) and fat tissue index (FTI),
normalized to height squared [16, 17].
Malnutrition-Inflammation Score (MIS) was used to
assess nutritional status. It consists of ten items: modifi-
cation in end-dialysis dry weight, dietary intake, comor-
bidities, functional capacity, gastrointestinal symptoms,
BMI, loss of subcutaneous fat, decreased fat stores or/
and signs of sarcopenia (according to SGA), serum albu-
min and total iron-binding capacity. Each item can
present four levels of severity, from 0 (normal) to 3 (se-
verely abnormal). Therefore, the MIS score can range
from 0 to 30, with a higher score reflecting greater mal-
nutrition and inflammation severity [18]. A score of 5 or
above was considered to be indicative of malnutrition.
Muscle function tests
All functional assessments were conducted by two
trained assessors before the beginning of the HD session,
in a quiet environment, using a standardized protocol,
and included the dynamometer handgrip strength
(HGS), the 6 min walking test (6MWT) and the Fatigue
Severity Scale (FSS) [19]. The HGS was measured on the
non-fistula arm using a Jamar hand dynamometer, con-
sidering the highest HGS value after three trials (with a
one-minute pause between trials) [20].
6MWT was performed according to the American
Thoracic Society guidelines. The respondents were asked
to walk for 6 min along a 30m corridor under medical
supervision, at the normal pace they used daily. Test re-
sults consisted of the total covered distance, measured in
m (with an accuracy of 1 m) [21].
Finally, muscular fatigue was assessed by FSS, a 9-item
self-report questionnaire where each item is scored 1–7.
The total score range from 9 to 63 and a score > 36 was
considered pathological.
Statistical analysis
Data are presented as mean ± standard deviation (SD) or
interquartile ranges (IQR), if not normally distributed
(as evaluated by Shapiro Test).
Analysis of variance (ANOVA), Student t-test or non-
parametric Mann-Whitney test, were used to assess the
differences among control group and HD patients.
Spearman-Rho was used to assess the correlations be-
tween Mstn and clinical and laboratory variables, while
logistic regression models were used to analyze the
associations (Stata 13.1, Stata Corporation, College Sta-




We enrolled 37 HD patients (69.6 ± 15 years, 14 females)
with a dialysis vintage of 35 (19.5–48) months. At the
time of enrollment, 24 patients (65%) were undergoing
thrice-weekly 4-h BHD, while 13 patients (35%) HDF.
32 patients (86%) were hypertensive, 12 patients (32%)
were diabetic and 12 patients (32%) were active smokers.
The main underlying nephropathies included glomerulo-
nephritis, nephroangiosclerosis, diabetic nephropathy
and adult dominant polycystic kidney disease.
Mean BMI was 26.4 ± 4.2 kg/m2, while mean pre-
dialytic potassium, albumin and CRP were 4.6 ± 0.7
mEq/l, 32 ± 4 (3.2 ± 0.4) g/dl and 0.76 (0.25–1.2) mg/dl,
respectively. Mean McAuley index was 5.6 ± 2. Consider-
ing a cut-off of ≤5.8, 23 patients (62%) resulted insulin-
resistant.
20 healthy subjects (48.5 ± 10 years, p < 0.01 vs HD, 8
females), with normal renal function (creatinine 78.2 ±
16 μmol/L) and mean BMI of 27 ± 2 kg/m2, constituted
the control I group.
Whole patient characteristics are shown in Table 1.
Myostatin profile
There was no significant difference in serum Mstn levels
between pre-dialysis HD and Control groups (4.7 ± 2.8
vs 4.4 ± 1.3 ng/ml, p = 0.8). Moreover, in the HD group
post-dialysis Mstn levels resulted significantly lower than
pre-dialysis ones (4.2 ± 2.6 ng/ml, p = 0.02). Finally, tak-
ing into consideration the different dialytic modalities,
we found no differences in Mstn levels, comparing pa-
tients undergoing BHD or HDF (4.7 ± 2.8 vs 4.6 ± 3 ng/
ml) (Fig. 1).
Nutritional parameters and functional tests
As recorded by BCM, mean LTI and FTI were 12.3 ± 2.9
and 14 ± 5.9 kg/m2, respectively. There were no signifi-
cant differences between female and male patients.
Mean MIS score was 14 ± 3. Considering a MIS cut-off
≥5, we demonstrated the presence of malnutrition in all
the evaluated HD patients.
All participants completed the functional assessment.
Mean HGS was 25.1 ± 9 kg, but it was significantly lower
in women than in men (19.8 ± 5.9 vs 27.7 ± 9.3 kg, p <
0.05). The average distance achieved in the 6MWT was
365 ± 79 m.
Finally, mean FSS was 45 ± 11, presenting a clear
pathological value (i.e. > 36) in 31 patients (83%)
(Table 2).
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Correlations
Correlation analysis showed a direct association between
pre-dialysis Mstn and LTI, albumin and phosphate serum
levels (Fig. 2), whereas there was a significant inverse asso-
ciation with age, BMI, FTI and MIS. Moreover, MIS re-
sulted inversely correlated with serum albumin levels and
LTI, while was directly correlated with age, CRP levels,
OH state (r = 0.44) and fatigue, expressed as FSS (r = 0.37,
p = 0.02) (Table 3). McAuley index, defining insulin resist-
ance (i.e. lower values correspond to increased risk of IR),
was inversely correlated with BMI and FTI and directly re-
lated to HD vintage and OH. HGS was directly correlated
with muscle mass, expressed as LTI (r = 0.41, p = 0.01),
and inversely correlated with age (r = − 0.35, p = 0.04).
Finally, in multivariate analysis, after adjustment for
age, sex and HD vintage, Mstn resulted inversely associ-
ated with FTI (β = − 1.055, p = 0.002).
Discussion
In this study, we tried to define the meaning of serum
Mstn in HD patients.
First, we evaluated the circulating levels of Mstn and
the potential effect of dialytic treatment on these levels,
taking into consideration different dialysis techniques
(BHD vs HDF). We found no differences in Mstn levels
between HD patients and healthy control, while there
was a significant slight decrease of Mstn after a single
Fig. 1 Serum Myostatin levels in HD patients. There were not significant differences in serum myostatin levels between healthy control subjects
(C) and patients undergoing hemodialysis. Post-dialysis there was a significant decrease in Myostatin levels compared with pre-dialysis values.
* p < 0.05





Age, (years) 69.6 ± 15
BMI, (kg/m2) 26.4 ± 4.2
Diabetes, n (%) 12 (32)
Time on dialysis, months (IQR) 35 (19.5–48)
Type of dialysis, n (%)
BHD, n (%) 24 (65)
HDF, n (%) 13 (35)
Serum potassium (mEq/L) 4.6 ± 0.7
Serum albumin (g/L) 32 ± 0.4
Prealbumin (g/L) 0.3 ± 0.08
Total cholesterol (mmol/L) 3.6 ± 0.9
Triglycerides (mmol/L) 1.8 ± 0.8
Phosphate (mmol/L) 1.6 ± 0.5
McAuley index 5.6 ± 2
CRP (mg/dl), IQR 0.76 (0.25–1.2)
Transferrin (g/L) 1.7 ± 0.3
spKT/V 1.66 ± 0.3
All values were determined in predialysis
Abbreviations: Body mass index (BMI), Bicarbonate-hemodialysis (BHD);
Hemodiafiltration (HDF), C-reactive protein (CRP), standard pool KT/V (spKT/V)
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HD session, confirming our previous data of a potential
modulation of serum Mstn by HD treatment [22]. How-
ever, in contrast with other reports, we did not observe
significant differences in Mstn levels between BHD and
HDF [14, 22].
This finding could be explained by many factors, in-
cluding the diverse assays used to measure circulating
Mstn, the different study design (crossover vs observa-
tional) and the small number of patients enrolled in
these studies that may have not allowed to discriminate
little differences between the two HD modalities.
Furthermore, basing on the known inhibitory effects of
Mstn on skeletal muscle growth, we investigated the hypo-
thetical use of serum Mstn level as a biomarker for muscle
wasting, a very common condition in HD patients, signifi-
cantly related to relevant clinical consequences.
Therefore, we studied circulating Mstn in relation to
nutritional and metabolic parameters and muscle func-
tion tests. Interestingly, we found that in HD patients
serum Mstn resulted directly correlated with muscle
mass, evaluated by BIA. Coherently, circulating Mstn re-
sulted inversely correlated with BMI, fat body content
and age, indicating that obese and older patients with
low muscle mass present low circulating Mstn levels.
This data was also reinforced by the evidence of direct
correlation of Mstn with albumin and phosphate levels,
often used as markers of good nutritional status, and its
inverse correlation with malnutrition, evaluated by MIS.
All these findings are in apparent contradiction with
those reported in skeletal muscle and suggest that circu-
lating Mstn reflects muscle mass content rather than
muscle wasting. On the other hand, this data is not so
surprising, since the actual relationship between serum
Mstn and skeletal muscle mass in humans remains con-
troversial. Indeed, while there is evidence of an inverse
correlation between serum Mstn and skeletal muscle
mass in elderly and patients affected by chronic diseases,
it has been also reported that low serum Mstn levels are
associated with low skeletal muscle mass in in heart
Table 2 Body composition and muscle function tests at the
time of clinical observation
Total population
N 37
Serum Myostatin (ng/ml) 4.7 ± 2.8
LTI, (kg/m2) 12.3 ± 2.9
FTI, (kg/m2) 14 ± 5.9
OH (L), IQRs 0.5 (−0.9_1.2)
MIS 14 ± 3
HGS (kg) 25.1 ± 9
Male (n.24) 27.7 ± 9.3
Female (n.13) 19.8 ± 5.9*
6MWT (m) 365 ± 79
FSS 45 ± 11
All values were determined in predialysis. * p < 0.05 vs males
Abbreviations: Lean Tissue Index (LTI), Fat tissue index (FTI), Body mass index
(BMI), Overhydration (OH), Malnutrition Inflammation Score (MIS), Hand-grip
strength (HGS), 6-min walking test (6MWT), Fatigue Severity Scale (FSS)
Fig. 2 Correlation between serum Myostatin and muscle mass in HD patients. There was a direct correlation between serum Mstn and muscle
mass (expressed as Lean Tissue Index-LTI). Linear regression analysis, r = 0.67, p < 0.0001
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failure patients with cachexia, such as in healthy old
adults [9, 10, 23, 24]. Similarly, in HD patients, while
Mstn has been found to be overexpressed in muscle and
strictly linked to inflammation and muscle atrophy, the
analysis of serum Mstn levels has shown contrasting re-
sults [13, 14, 22, 25]. Therefore, it seems there could be
a discrepancy between muscular and circulating Mstn,
whose explanation is not so clear. First, it is possible that
circulating Mstn not necessarily reflects its intramuscu-
lar concentration, since the protein may be also pro-
duced from other tissues or undergoes degradation.
Secondly, it is conceivable that other extracellular matrix
proteins might interact with Mstn and Mstn-linked mol-
ecules, regulating Mstn expression and TGF-β signalling
pathway in muscle cells [26].
However, when we looked at the functional meaning
of serum Mstn, we did not find correlations among
serum Mstn and functional tests exploring muscle
strength, endurance and fatigue.
Analogously, when we studied the metabolic parame-
ters, we did not find significant correlations among circu-
lating Mstn and metabolic pathways, including lipids and
insulin resistance (IR), evaluated by McAuley index. Also
in this case, as well as for that reported for muscle mass,
the relationship between circulating Mstn and IR is con-
troversial and matter of debate. Indeed, while previous
studies showed elevated Mstn levels in obese patients with
hyperinsulinemia and IR, configuring a condition in which
IR might potentiate the inhibitory effect of Mstn on
muscle growth [27], high serum Mstn has also been re-
ported to be associated with favourable metabolic profiles
and a lower prevalence of metabolic syndrome [28].
Therefore, overall these findings indicate that while
circulating Mstn seems to reflect the muscle mass, its
actual clinical significance and utility in HD patients re-
mains questionable.
Beyond data on Mstn, our study highlighted some other
collateral findings that are worthy to be considered. First
of all, we confirmed that malnutrition is very common in
HD patients. In our study this condition, which actually
implies a complex and multifaceted pathogenesis, resulted
related to age, inflammation (evaluated as CRP levels) and
overhydration (OH) state. In particular, the correlation of
OH with malnutrition and inflammation has been also re-
ported in other studies [29] and is of peculiar interest in
HD patients, since volume control is one of the main
problems in the daily management of these patients.
Regarding muscle function tests, we found that HGS was
directly correlated with muscle mass, as also previously re-
ported, and inversely related to age, while self-reported
muscle fatigue correlated with malnutrition, which may
probably represent the functional correspondent.
We are aware that our study presents some limita-
tions, mainly due to the observational design and the
small number of patients evaluated with control subjects
younger than HD patients.
Indeed, while a single determination of circulating
Mstn is related to muscle mass, it is possible that the
periodical monitoring (i.e. the time trend) of Mstn levels
could provide useful information about muscle loss and
progression of cachexia over the time.
Moreover, it is conceivable that the study of complex
processes, such as muscle wasting and malnutrition in HD,
should not be limited to the evaluation of a specific marker.
For example, beyond Mstn, other molecules, such as
cytokines, activins and follistatin, may regulate muscle
growth and metabolism [30]. In particular, among
them, Activin A, which shares the receptor with Mstn
(i.e. ActRIIB) and has been related with muscle loss
in cancer, seems worthy of being investigated as an
additional biomarker of muscle wasting, also in HD
patients [31, 32].
Table 3 Correlations among Myostatin serum levels, nutritional and functional parameters in HD patients
N = 37 Age HD-age MSTN Phosphate BMI LTI FTI CRP Albumin McA MIS
Age 1
HD-age 0.12 1
MSTN −0.63§ 0.01 1
Phosphate − 0.44+ − 0.08 0.4* 1
BMI 0.06 −0.09 − 0.4* − 0.06 1
LTI −0.68 § 0.143 0.82 § 0.38* −0.45 1
FTI 0.28 −0.2 −0.65 § − 0.18 − 0.18§ −0.7 § 1
CRP 0.27 0.17 −0.19 −0.12 0.05 −0.17 −0.06 1
Albumin −0.09 −0.04 0.35* 0.02 0.14 0.3 −0.01 −0.07 1
McA 0.19 0.43+ 0.06 −0.09 −0.54+ 0.18 −0.45+ − 0.006 −0.18 1
MIS 0.47+ −0.06 −0.39* − 0.04 −0.29 − 0.44+ −0.02 0.37* −0.43* 0.12 1
Correlation coefficients are shown. * p < 0.05; + p < 0.01; § p < 0.001
Abbreviations: Hemodialysis (HD), Myostatin (Mstn), Body mass index (BMI), Fat tissue index (FTI), lean tissue index (LTI), Overhydration (OH), C-reactive protein
(CRP), McAuley index (McA), Malnutrition Inflammation Score (MIS)
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Finally, it should be underlined that the study of circu-
lating Mstn could also be made difficult by technical
limitations, since in the Literature there is some concern
about the use of ELISA-based approaches to measure
Mstn concentration, mainly because Mstn immunoreac-
tivity does not necessarily equal to its bioactivity [33].
Conclusions
In conclusion, we think that the relationship between
Mstn and muscle mass and nutritional status candidate
circulating Mstn as an interesting new player in the
regulation of skeletal muscle trophism. This is particu-
larly relevant, since Mstn is currently object of many re-
searches on the potential role of its pharmacological
inhibition, aiming to promote muscle mass increase and
improve the metabolic profile and frailty in different dis-
ease conditions [34–36]. However, current evidence is
not strong enough to support the use of serum Mstn to
diagnose muscle wasting and malnutrition or to monitor
the responses to the treatments in HD patients. There-
fore, further studies, possibly prospective and performed
with more accurate analytical methods (like mass spec-
trometry), are needed to elucidate the potentialities of
circulating Mstn as a biomarker and its utility in detect-
ing patients at risk for wasting.
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